The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption ...
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, ...
The ELN 2024 framework offers better stratification for AP/BP MPN, but gaps remain between intermediate and adverse groups. The study analyzed 211 patients, showing modest response rates and ...
Advancements in Interoperability: Achieving Anatomic Pathology Reports That Adhere to International Standards and Are Both Human-Readable and Readily Computable Favorable, intermediate, and adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results